StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)

Close on Nov 16, 2026Market cap $1.56BP/E –Yield –

Recursion Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Recursion Pharmaceuticals's gross margin for the twelve months ending Jun 30, 2026 was 3.5%. For fiscal 2025 it was 5.0%, against 23.1% the year before. The highest annual figure on record is 100.0% in fiscal 2020.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 20255.0%−18.1
FY2024Dec 31, 202423.1%+18.7
FY2023Dec 31, 20234.5%+25.6
FY2022Dec 31, 2022-21.2%−121.2
FY2021Dec 31, 2021100.0%+0.0
FY2020Dec 31, 2020100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-49.8%−44.9
Q1 FY2026Mar 31, 2026-93.0%−44.9
Q4 FY2025Dec 31, 202559.8%+241.3
Q3 FY2025Sep 30, 2025-183.8%−237.5
Q2 FY2025Jun 30, 2025-4.9%−41.1
Q1 FY2025Mar 31, 2025-48.0%−67.1
Q4 FY2024Dec 31, 2024-181.4%−190.7
Q3 FY2024Sep 30, 202453.7%+57.0
Q2 FY2024Jun 30, 202436.2%+21.4
Q1 FY2024Mar 31, 202419.1%+21.6
Q4 FY2023Dec 31, 20239.3%−11.5
Q3 FY2023Sep 30, 2023-3.3%+13.8
Q2 FY2023Jun 30, 202314.8%+100.2
Q1 FY2023Mar 31, 2023-2.6%+43.7
Q4 FY2022Dec 31, 202220.7%−79.3
Q3 FY2022Sep 30, 2022-17.1%−117.1
Q2 FY2022Jun 30, 2022-85.4%−185.4
Q1 FY2022Mar 31, 2022-46.2%−146.2
Q4 FY2021Dec 31, 2021100.0%–
Q3 FY2021Sep 30, 2021100.0%–
Q2 FY2021Jun 30, 2021100.0%–
Q1 FY2021Mar 31, 2021100.0%–

More Recursion Pharmaceuticals figures

See a number that looks wrong?